Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ultragenyx Pharmaceutical Inc. filings document a rare-disease biopharmaceutical business with approved medicines, investigational genetic-disease therapies, and a Nasdaq-listed common stock capital structure. Form 8-K reports include operating results, financial guidance, FDA communications, clinical-study data, and risk language tied to drug development, regulatory review, manufacturing, funding needs, competition, and commercialization.
Proxy materials describe annual-meeting matters, board and compensation governance, equity compensation, and stockholder voting. Recent current reports also record restructuring and cost disclosures, employment-related equity plans, and material updates for programs including UX111, UX016, DTX301, DTX401, and GTX-102.
Ultragenyx Pharmaceutical Inc. director Michael Narachi received equity compensation in the form of restricted stock units and options. He was granted 7,751 RSUs that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. He also received stock options for 14,058 shares of common stock at an exercise price of $25.80 per share, vesting on the same schedule and expiring on May 14, 2036. Following the RSU grant, his direct common stock holdings increased to 40,441 shares.
Ultragenyx Pharmaceutical Inc. director Daniel G. Welch reported equity awards from the company. He received 7,751 shares of Common Stock as a grant of restricted stock units (RSUs) under the 2023 Incentive Plan, with no cash paid per share, bringing his direct Common Stock holdings to 40,441 shares.
He was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.
Ultragenyx Pharmaceutical Inc. director Deborah Dunsire received new equity awards as part of her compensation. She was granted 7,751 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. She also received stock options for 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036, with the options vesting on the same schedule. Following these awards, she directly holds 38,566 shares of Common Stock and 14,058 stock options.
Ultragenyx Pharmaceutical Inc. reported results of its Annual Meeting of Stockholders held on May 14, 2026. As of the record date of March 23, 2026, 98,317,221 shares of common stock were outstanding and entitled to vote, and 84,786,388 shares were represented in person or by proxy.
Stockholders elected Class I directors Emil D. Kakkis, M.D., Ph.D., Shehnaaz Suliman, M.D., and Daniel G. Welch to serve until the 2029 annual meeting. They also approved the Third Amended and Restated 2023 Incentive Plan, with 50,659,150 votes for and 22,888,600 against.
Shareholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In an advisory, non-binding vote, stockholders approved executive compensation, with 70,945,277 votes for and 2,594,517 against.
State Street Corporation reported beneficial ownership of 5,021,441 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 5.1% of the class as of 03/31/2026. The filing lists shared voting power of 4,769,004 shares and shared dispositive power of 5,021,441 shares. The filing is a Schedule 13G disclosure signed on 05/12/2026 by Elizabeth Schaefer.
Ultragenyx Pharmaceutical Inc. executive Eric Crombez, EVP and Chief Medical Officer, sold 344 shares of common stock at $24.96 per share on May 5, 2026. According to the footnotes, these shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). After this tax-related sale, Crombez directly holds 111,189 shares of Ultragenyx common stock.
Ultragenyx Pharmaceutical Inc. reported a net loss of $185 million for the quarter ended March 31, 2026, on $136 million in total revenues, down 2% year over year. Product sales were $89 million, led by Crysvita at $46 million, while Crysvita royalty revenue contributed $47 million.
Research and development expenses rose to $187 million, driven by manufacturing and late-stage work on gene therapies DTX401 and UX111 and biologic programs GTX‑102 and UX143. Selling, general and administrative costs were stable at $88 million.
The company booked $30 million of restructuring charges tied to a February 2026 plan that cut its workforce by about 10% and curtailed certain activities, including UX143 manufacturing. Cash, cash equivalents and marketable securities totaled $534 million, while liabilities for sales of future Crysvita royalties reached $1.2 billion.
Ultragenyx Pharmaceutical reported first quarter 2026 revenue of $136 million, slightly below $139 million a year earlier, with Crysvita contributing $93 million, Dojolvi $18 million, Evkeeza $18 million and Mepsevii $7 million. Product sales were $89 million and royalty revenue $47 million.
The company posted a net loss of $185 million, or $1.84 per share, compared with a $151 million loss, or $1.57 per share, in 2025 as total operating expenses rose to $305 million. Cash, cash equivalents and marketable securities were $534 million as of March 31, 2026, down from $737 million at year-end, with $197 million of net cash used in operations.
Ultragenyx reaffirmed its 2026 guidance, targeting total revenue of $730–$760 million and combined R&D and SG&A expenses flat to slightly down versus 2025, and continues to aim for profitability in 2027. The company highlighted two gene therapy BLAs under FDA Priority Review for DTX401 and UX111, with PDUFA action dates on August 23, 2026 and September 19, 2026, respectively, and positive longer-term data from the GTX-102 Angelman syndrome program ahead of a Phase 3 readout in the second half of 2026.
Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer Howard Horn reported an open-market sale of 4,683 shares of common stock at $24.90 per share. After this transaction, he directly owns 110,342 shares, which the disclosure notes include shares underlying RSUs that are subject to vesting conditions.